We are live on ! Find out more

First Trust NYSE Arca Biotechnology Index Fund

FBT

Market cap $3.02B

271.17 USD

-3.90

1.42%

At close Updated Nov 12, 4:00 PM EST

1 day

-1.42%

5 days

2.94%

1 month

2.75%

3 months

4.72%

6 months

27.47%

Year to date

30.54%

1 year

33.57%

5 years

69.81%

10 years

164.89%

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 35.7%

Neutral 57.1%

Negative 7.1%

Zacks Investment Research

Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?

Making its debut on 06/19/2006, smart beta exchange traded fund First Trust NYSE Arca Biotechnology ETF (FBT) provides investors broad exposure to the Health Care ETFs category of the market.

Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?

The Motley Fool

Drug Makers or Biotech Bets: Which ETF Is the Better Buy, State Street's XPH or First Trust's FBT?

State Street SPDR S&P Pharmaceuticals ETF offers a lower expense ratio of 0.35% compared to 0.55% for the First Trust fund. First Trust NYSE Arca Biotechnology Index Fund has delivered higher total returns over the past one-year and five-year periods.

Drug Makers or Biotech Bets: Which ETF Is the Better Buy, State Street's XPH or First Trust's FBT?

The Motley Fool

Which Is the Better Buy: iShares' Pharma ETF IHE or First Trust's Biotech Fund FBT?

iShares U.S. Pharmaceuticals ETF has a lower expense ratio than the First Trust NYSE Arca Biotechnology Index Fund. First Trust NYSE Arca Biotechnology Index Fund maintains a more concentrated portfolio.

Which Is the Better Buy: iShares' Pharma ETF IHE or First Trust's Biotech Fund FBT?

Zacks Investment Research

Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?

Looking for broad exposure to the Healthcare - Biotech segment of the equity market? You should consider the First Trust NYSE Arca Biotechnology ETF (FBT), a passively managed exchange traded fund launched on June 19, 2006.

Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?

Zacks Investment Research

ETFs That You May Consider Amid a Strengthening Biotech Outlook

Drug innovation, AI and rising M&A activity are boosting biotech optimism. Discover ETFs offering exposure to the sector.

ETFs That You May Consider Amid a Strengthening Biotech Outlook

The Motley Fool

Which Healthcare ETF Is the Better Buy: Simplify's Mission-Driven PINK or First Trust's Biotech FBT?

First Trust NYSE Arca Biotechnology Index Fund tracks a concentrated index of 30 biotech stocks, while Simplify Health Care ETF is an actively managed fund with broader healthcare exposure. Simplify Health Care ETF features a lower expense ratio and has experienced a significantly lower maximum drawdown over the last five years compared to the First Trust fund.

Which Healthcare ETF Is the Better Buy: Simplify's Mission-Driven PINK or First Trust's Biotech FBT?

The Motley Fool

Which Healthcare ETF Is the Better Buy: Invesco's Broad RSPH or First Trust's Biotech FBT?

First Trust NYSE Arca Biotechnology Index Fund has delivered significantly higher 1-year total returns but with greater volatility and a deeper maximum drawdown. Invesco S&P 500 Equal Weight Health Care ETF provides broader sector coverage, whereas the First Trust fund is a concentrated play on 30 biotechnology firms.

Which Healthcare ETF Is the Better Buy: Invesco's Broad RSPH or First Trust's Biotech FBT?

The Motley Fool

Which Healthcare ETF Is the Better Buy: iShares' Global IXJ or First Trust's Biotech FBT?

iShares Global Healthcare ETF offers a lower expense ratio and broader sector exposure than First Trust NYSE Arca Biotechnology Index Fund. First Trust NYSE Arca Biotechnology Index Fund focuses exclusively on biotechnology while iShares Global Healthcare ETF includes pharmaceuticals and equipment.

Which Healthcare ETF Is the Better Buy: iShares' Global IXJ or First Trust's Biotech FBT?

The Motley Fool

Better Biotechnology ETF: First Trust FBT vs. VanEck BBH

The First Trust NYSE Arca Biotechnology Index Fund has outperformed the VanEck Biotech ETF on a one-year basis and over the last five years. The VanEck Biotech ETF offers a lower expense ratio of 0.35% compared to 0.55% for the First Trust fund.

Better Biotechnology ETF: First Trust FBT vs. VanEck BBH

Zacks Investment Research

Biotech ETFs to Buy as Cancer Drug Breakthroughs Accelerate

Biotech ETFs offer diversified exposure to oncology innovation as cancer funding surges and the global oncology drug market expands.

Biotech ETFs to Buy as Cancer Drug Breakthroughs Accelerate

See News Rankings

Price charts implemented using Lightweight Charts™